There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The onset mechanism of ALI/ARDS and subsequent tissue injury are considered to be
associated with neutrophil elastase, and the main causes of ALI/ARDS are considered
to be sepsis or aspiration pneumonia. In Japan, sivelestat sodium hydrate (Elaspol),
a selective elastase inhibitor, was approved in 2002 for ALI/ARDS accompanied by SIRS,
and this medicine has been evaluated in a clinical situation. In this study, we performed
a retrospective comparison of the sivelestat sodium administration between two groups
of patients: Group Elaspol, consisting of 308 patients (209 males and 99 females,
aged 66 ± 15 years) with ALI/ARDS accompanied by SIRS who were treated with sivelestat
sodium at a dose of 0.2 mg/kg/hour for 72 hours or more, after approval of this drug;
and Group Control, consisting of 41 patients (28 males and 13 females, aged 66 ± 14
years) with ALI/ARDS accompanied by SIRS who were treated in the ICU under similar
conditions, but using traditional methods for respiratory control, prior to approval
sivelestat sodium. The APACHE II scores of Group Elaspol and Group Control were 23
± 9 and 23 ± 8, SOFA scores were 8.7 ± 3.8 and 8.9 ± 4.1, and the lung injury scores
were 2.1 ± 0.7 and 2.1 ± 0.6, respectively, with no significant differences between
the groups. The initial PEEP value of Group Elaspol was 5.9 ± 3.3, which was significantly
higher than that of Group Control (3.4 ± 2.7 cmH2O). The PaO2/FIO2 ratios under mechanical
ventilation management 24, 48 and 72 hours after the beginning of drug administration
were 209 ± 87, 222 ± 92, and 222 ± 82 mmHg in Group Elaspol, and were 191 ± 91, 207
± 91, and 211 ± 100 mmHg in Group Control. The ventilator-free days of Group Elaspol
and Group Control were 18 ± 9 and 10 ± 12 days, respectively, and these values showed
a significant difference (P < 0.001). Furthermore, the survival rate after 28 days
was significantly higher in Group Elaspol than in Group Control (Group Elaspol: 75%,
Group Control: 52%; P < 0.001). These results suggest that sivelestat sodium hydrate
is a good option as a treatment strategy for neutrophil elastase-associated septic
ALI/ARDS accompanied by SIRS.